Race influences warfarin gene-dose association
Introduction
The recognition of racial differences in disease diagnosis, treatment, and outcomes has led the National Institutes of Health to encourage broad racial representation in developing the evidence base for treatment. For warfarin, the most widely used oral anticoagulant; investigators have met this charge through individual [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and collaborative efforts [14] [15] [16] to identify factors that influence dose requirements. This body of work provides a robust case-study for understanding racerelated differences in drug response.
The significant inter-patient variability in the dose requirements necessary for optimal anticoagulation poses a unique challenge for warfarin therapy. 17 Investigations have identified clinical (e.g. age, co-medications) and genetic factors that explain a significant proportion of dose variability. Although several genes influence warfarin dose, single nucleotide polymorphism (SNPs) in Cytochrome P450 2C9 (CYP2C9, the principal enzyme that metabolizes warfarin) and Vitamin K epoxide reductase complex 1 (VKORC1, the target protein inhibited by warfarin) account for significant dose variability. 18, 19 This evidence underpins the prevailing hypothesis that genotype-guided therapy should improve dosing accuracy, and this in turn should improve anticoagulation control measured as percent-
time-in-therapeutic-range (PTTR). Two clinical trials, the European Pharmacogenetics of
Anticoagulant Therapy (EU-PACT) 20 and the Clarification of Oral Anticoagulation through Genetics (COAG), 21 evaluated whether genotype-guided dosing improved PTTR, reporting incongruous results. Moreover, African Americans receiving genotype-guided dosing had lower PTTR than those receiving clinical-guided dosing. 21 For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From
We hypothesize that the effect of clinical and genetic factors on warfarin dose differs by race and that compared to race-combined dosing models, race-stratified models improve prediction accuracy for both race groups. We use this as a framework to reconcile the evidence from observational and interventional warfarin pharmacogenetic studies and discuss implications of combining race groups in analysis.
Methods

Study Population
Participants (>20 years old) initiating warfarin with the target international normalized ratio (INR) of 2-3 were enrolled at the beginning of treatment in an inception cohort under the approval of the Institutional Review Boards of the University of Alabama at Birmingham and Emory University.
Clinical and Genetic Variables
Patient demographics, indications for therapy, comorbidities, and medications were collected as previously reported. [4] [5] [6] 22 In addition to VKORC1 (rs9923231), CYP2C9 (*2 
Outcome Variable
Dose (mg/day; log transformed to attain normality) was defined as the average maintenance dose after the attainment of three consecutive INRs in target range measured at least 2 weeks apart.
Statistical Analyses
Analysis of variance was used to assess group differences for continuous variables and chi-square for categorical variables. To evaluate the effect of predictors on warfarin dose, we first restricted the multivariable linear regression analysis to include predictors (age, body surface area [BSA], smoking status, venous thromboembolism (VTE) versus non-VTE indication, amiodarone co-therapy, and CYP2C9*2, CYP2C9*3, and VKORC1) included in COAG (Model 1). To test whether the effect of predictors differed by race, we first conducted multivariable analysis adjusting for race (with and without predictor-race interactions) and then conducted race-stratified analysis.
Next, we incorporated additional variables (not included in the COAG) that have been reported to influence warfarin dose (Model 2). These include chronic kidney disease (CKD), 22, 25 co-therapy with statins and antiplatelets, CYP4F2, African American specific CYP2C9 SNPs (*5, *6, *8, *11), rs12777823, FPGS, EPHX1, GGCX and CALU. We also included factors that showed significant racial differences in prevalence in our cohort and retained these factors in the model at a nominal p-value of <0.2. All analyses were conducted with SAS version 9.3 at a bidirectional alpha level of 0.05. We evaluated the impact of predictors included in the algorithm implemented in COAG (Model 1). Dose changes associated with each predictor in race-combined and race-stratified analysis are presented in Table 2 . To assess if the impact of predictors differed by race, we evaluated predictor-race interactions in the entire cohort. higher dose (per allele) in European Americans but not in African Americans; however, the parameter estimates were not significantly different. Table 4 presents the proportion of dose variability uniquely explained by clinical and genetic in race-combined and race-stratified analysis using dosing algorithms shown in Table 2 These findings have fuelled discussion regarding the utility of genotype-guided-dosing, with investigators suggesting reasons for the null association with PTTR and the discordant findings by race in COAG. These include racial differences in CYP2C9*2, CYP2C9*3 and VKORC1 frequencies, lack of inclusion of African American specific variation, differences in indication, and subtle stratification introduced by age across race. Moreover, the differences in PTTR improvement (7% vs. 3%) among Europeans in EUPACT versus COAG have been attributed to differences in study design, initiation-algorithms, and differences in comparator arms.
We propose that differences in the proportional African representation can explain PTTR differences among COAG participants. As the algorithms adjust (rather than stratify) for race, 
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The 43% African Americans in our cohort allowed robust assessment of the impact of clinical and genetic factors on warfarin dose by race. Concordant with previous reports, dose-prediction models explained greater dose variability among European Americans than African Americans.
Clinical predictors account for a greater portion of variability in African Americans while genetic predictors account for a greater portion of the variability in European Americans.
To reconcile the evidence from observational and interventional studies, it is important to remember that these algorithms were derived from cohorts comprised largely of European Americans, with African Americans comprising a smaller proportion (9% IWPC; 15% Gage et al).
11,14 Therefore the parameter-estimates are potentially weighted towards race-groups with higher representation. Second, the algorithms assume that predictors have the same impact for all race groups, assigning a fixed effect-size (beta-coefficient) to each predictor regardless of race.
Therefore the differential effect of a predictor by race (if one exists) is attenuated. This attenuation is likely to occur in both race-groups but may be more pronounced in the lessrepresented race-group. In contrast, as 98.6% EUPACT participants were of European descent, attenuation of parameter estimates (if any) was inconsequential.
Consider, for example, the effect of CYP2C9*2. The literature supports the CYP2C9*2-decreased dose association among European Americans. 33, 34 However, to our knowledge, the independent influence of CYP2C9*2 on warfarin dose in African Americans is not established. European Americans (MAF=14%). 16 As we show in our race-combined analysis, assigning a fixed-effect would result in a 6% dose reduction for both African Americans (rather than the 12% reduction) and European Americans (in whom no adjustment is needed).
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Improvement in dose prediction (for both race groups) can be achieved by using race stratified algorithms. For example, in African Americans, the dosing algorithm predicted a greater portion of the dose variability compared to that predicted by Hernandez et al (34% vs. 27%).
36 Therefore we recommend using race-stratified algorithms to guide dosing over race-adjusted algorithms as they incorporate clinical and genetic factors influencing dose requirements in that race group and allow the use of race-specific effect-size (parameter estimates) to personalize dosing.
While we assessed differential effect of predictors among African and European Americans, we recognize that these results may not be generalizable to Hispanics and Asians. 37 Additional studies are needed to identify predictors that may differentially influence warfarin response in these race groups. Moreover, it is likely that incorporation of other genetic 13, 38, 39 and clinical factors, not assessed in this study, may further improve dose prediction and alter the effect-sizes of the predictors evaluated herein. We recognize this limitation.
Finally, these results bring into focus the broader implications related to racial heterogeneity in pharmacogenetic studies; demonstrating that the effect of predictors varies by race; that these effects are dependent on predictor prevalence and its biological effect (which cannot be presumed to be uniform). This highlights the need for adequate racial representation to facilitate identification of the differential impact of a predictor by race and enable adaptive algorithms that can incorporate race-specific effect-size to personalize therapy. 
